Ansa Biotechnologies · Mar 2026
Ansa named Matthias Arenskötter COO to lead global operations, manufacturing, supply chain, and quality systems.
Next-generation DNA synthesis using enzymes
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Ansa Biotechnologies is a privately held Emeryville-based DNA synthesis company that uses proprietary enzymatic technology to produce custom, sequence-perfect DNA fragments and clonal DNA, including ultra-long constructs up to 50 kb, for life-science research and industrial applications.
Primary product
Custom enzymatic DNA synthesis services (DNA Fragments, Clonal DNA, XL Clonal DNA)
Founded
2018
Headquarters
Emeryville, California, United States
Team size
60-70 employees
Industry
Biotechnology Research
Sub-industry
Enzymatic DNA synthesis / synthetic biology
Offices
1198 65th St #250, Emeryville, CA 94608
Business model
B2B custom DNA synthesis services
Catalog DNA products
Direct sales to researchers and institutions
Funding
Stage
Series B
Total raised
$183.1M
Latest round
Series B · Oct 2025
Latest amount
$54.4M
Oct 2025 · Cerberus Ventures
Apr 2022 · Northpond Ventures
Oct 2021
Jun 2020 · Horizon Ventures
Jun 2019 · National Science Foundation
People & investors
Leadership
Chief Executive Officer
Chief Financial Officer and Chief Business Officer
Matthias Arenskötter
Chief Operating Officer
Chief Scientific Officer and co-founder
Chief Technology Officer and co-founder
Dave Bullis
Vice President, Strategic Marketing
Scott Fay
Vice President, Informatics
Evan King
Vice President, Sales
Nick Hurt
Vice President, Legal
John Trust
Vice President, Finance
Founders
Co-founder
Work & culture
Mission-driven and high-performing, with an emphasis on curiosity, rigor, accountability, and cross-disciplinary teamwork to solve difficult DNA-synthesis problems.
Compensation
Public careers materials describe competitive, experience-based base salaries plus stock options; no public salary bands were found. Benefits include medical, dental, vision, 401(k), holidays, flexible vacation, and parental leave.
Benefits
Competitive base salaries
Stock options
Medical insurance
Dental insurance
Vision insurance
401(k) retirement planning
Company holidays
Flexible vacation time
Company-encouraged vacation time
Parental leave
Product & market
Pricing
Transparent, length- and complexity-based pricing with published prices for fragments and clonal DNA, plus quote-based pricing for custom orders; guaranteed ship dates are part of the offer.
Differentiators
- —Proprietary enzymatic DNA synthesis instead of phosphoramidite chemistry
- —No harsh chemicals
- —Direct synthesis of complex DNA without assembly up to 900 bp
- —Ultra-long clonal DNA up to 50 kb
- —Sequence-perfect / sequence-verified outputs
- —Industry-only on-time guarantee
- —Transparent published pricing
- —U.S.-based manufacturing
Technology
Proprietary TdT-dNTP conjugate enzymatic DNA synthesis
Aqueous-buffer synthesis process
Direct synthesis without assembly up to 900 bp
XL clonal DNA synthesis up to 50 kb
Sequence-perfect clonal DNA production
Sequence-verified linear double-stranded DNA fragments
Long-read sequencing quality control
Proprietary informatics/QC pipeline
Custom-built manufacturing instruments
U.S.-based manufacturing
Customers
Hexagon Bio
Terrain Bio
Allen Institute’s Seattle Hub for Synthetic Biology
University of Maryland, College Park
George Church / Harvard Medical School and MIT
Competitors
Twist Bioscience
Integrated DNA Technologies (IDT)
GenScript
DNA Script
Evonetix
Scale & contact
Estimated revenue
$1M-$10M
Estimated monthly visits
22.6K
Traffic estimate as of Jun 2026
Latest news
Ansa Biotechnologies · Jan 2026
IDT and Ansa announced a strategic collaboration making Ansa Clonal DNA and XL Clonal DNA available to IDT customers for longer, more complex constructs.
Business Wire · Oct 2025
Launch of 50 kb Clonal DNA, described as the longest sequence-perfect synthetic DNA commercially available, backed by Ansa's on-time guarantee.
Business Wire · Oct 2025
Series B financing closed and committed capital totaled $54.4M, led by Cerberus Ventures, to expand manufacturing and product development.
Business Wire · May 2025
Ansa opened early access orders for complex DNA up to 50 kb, targeting long and complex constructs in research and therapeutic workflows.
Jobs and careers at Ansa Biotechnologies
5 jobs at Ansa Biotechnologies
TEMPORARY CONTRACTOR - Manufacturing Associate, DNA Synthesis : Sunday - Wednesday, Swing Shift
On-site
Manufacturing
Emeryville, CA; Emeryville, California, United States
2w ago
On-site
Full-time
Scientist, Molecular Biology
On-site
Research & Development
Emeryville, CA; Emeryville, California, United States
2w ago
On-site
Full-time
Research Associate, Molecular Biology
On-site
Biochemistry
Emeryville, CA; Emeryville, California, United States
1mo ago
On-site
Full-time
Director of Accounting
On-site
Finance
Emeryville, CA; Emeryville, California, United States
1mo ago
On-site
Full-time
Staff Software Systems Developer
On-site
Informatics
Emeryville, CA
1mo ago
On-site
Full-time